Cargando…
Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer
SIMPLE SUMMARY: Androgen deprivation therapy is the most effective and widely used treatment for advanced prostate cancer, but its efficacy is highly variable among patients. Therefore, the identification of potent prognostic biomarkers is needed to determine patients at risk. We demonstrated that M...
Autores principales: | Chang, Hao-Han, Lee, Cheng-Hsueh, Chen, Yei-Tsung, Huang, Chao-Yuan, Yu, Chia-Cheng, Lin, Victor C., Geng, Jiun-Hung, Lu, Te-Ling, Huang, Shu-Pin, Bao, Bo-Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750592/ https://www.ncbi.nlm.nih.gov/pubmed/35008387 http://dx.doi.org/10.3390/cancers14010223 |
Ejemplares similares
-
TNFRSF13B is a potential contributor to prostate cancer
por: Li, Chia-Yang, et al.
Publicado: (2022) -
NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
por: Huang, Shu-Pin, et al.
Publicado: (2021) -
An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
por: Javeed, Saira, et al.
Publicado: (2022) -
Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2–MSH6 complex
por: Banerjee, Sreeparna, et al.
Publicado: (2005) -
Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2–MSH6 complex
por: Banerjee, Sreeparna, et al.
Publicado: (2005)